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Abstract
Introduction  Current concepts of the pathophysiology of acute
pancreatitis suggest that disease progression from acinar injury to
systemic illness involves a complex interplay between cellular and
soluble inflammatory mediators and endothelial beds. To date,
there is no specific pharmacologic intervention for acute
pancreatitis. Death from acute pancreatitis remains a major issue,
and late deaths are often related to haemorrhage and are
associated with unresolved intra-abdominal sepsis. Drotrecogin
alfa, an analogue of endogenous protein C, has antithrombotic,
anti-inflammatory and profibrinolytic properties, and it has been
shown to reduce mortality in clinical sepsis. Modulation of the
coagulation cascade, although probably essential to the mode of
action of drotrecogin alfa, can lead to an increased risk of bleeding.
Objective The findings of the PROWESS trial have led to a more
widespread use of drotrecogin alfa in sepsis and, critically, in
sepsis-related conditions. The present article provides a concise
summary of the interaction between the pathophysiology of acute
pancreatitis and the modes of action of drotrecogin alfa, placing
particular emphasis on the risks related to haemorrhage. Attention
is further drawn to the reports of use of drotrecogin alfa in severe
acute pancreatitis.
Conclusions  Synthesis of current knowledge on the modes of
action and the side-effect profiles of drotrecogin alfa into a
practical management algorithm must accept that evidence in this
field is changing rapidly. At present there is insufficient evidence to
justify the use of drotrecogin alfa in the early stages of this disease.
In the later stages, when the probability of infection is
proportionately greater, it is probable that intensive care clinicians
will turn to drotrecogin alfa, in particular, in the setting of recent-
onset organ dysfunction in established severe acute pancreatitis.
Although this can be justified by extrapolation of the evidence from
the PROWESS trial, practical critical care management in this
setting must not overlook the need to rule out infection of necrosis,
and must further be cognisant of the specific risks of haemorrhage
in patients with prolonged pancreatitis and pancreatic necrosis.
The early stages of severe acute pancreatitis are
characterised by a profound systemic inflammatory response
[1]. Current evidence is equivocal regarding the role of
infective agents at this stage of the disease process.
Although there is increased intestinal permeability to
macromolecules associated with a fall in endotoxin antibody
in severe disease, use of the polymerase chain reaction fails
to show early evidence of circulating bacterial genomic
products [2].
In contrast, the later stages of severe acute pancreatitis are
dominated by the sequelae of peri-pancreatic sepsis [3].
Although peri-pancreatic sepsis follows a similar course to
other forms of intra-abdominal sepsis, a specific disease-
related complication is the high risk of catastrophic intra-
abdominal haemorrhage [3]. The pathophysiology of bleeding
at this stage of the disease is multifactorial but may be related
to the effects of chronic exposure to pancreatic juice in the
lesser sac as a consequence of pancreatic ductal blow-out [4].
The search for treatments for severe sepsis has increasingly
focused on the interplay between inflammation, microvascular
coagulation and endothelial cell injury, and this has led to the
development of drotrecogin alfa (recombinant human
activated protein C) [5]. Drotrecogin alfa (Xigris; Eli Lilly,
Indianapolis, IN, USA) is a 55 kDa glycoprotein analogue of
endogenous protein C that is synthesised and secreted by
genetically engineered human cells [5]. Endogenous protein C
is a vitamin K-dependent glycoprotein synthesised by the
liver. Under normal physiological conditions the protein C
pathway plays an important role in the maintenance of
haemostasis and the modulation of inflammation. Activation of
protein C by thrombin-dependent endothelial binding inhibits
thrombin generation and stimulates fibrinolysis [6]. In
addition, activated protein C has anti-inflammatory properties
related, in part, to inhibition of monocyte tumour necrosis
factor alpha production and the modulation of E-selectin
expression by endothelial cells [7]. The conversion of protein C
to activated protein C is impaired during sepsis, and reduced
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levels of markers of activated protein C correlate with
increased morbidity in patients with sepsis [8]. It has been
known for some time that similar changes in protein C
activation occur in experimental acute pancreatitis [9].
In 2001, the PROWESS trial group reported the phase III
randomised trial of drotrecogin alfa in 1690 patients with
severe sepsis [10]. The principal outcome was an absolute
reduction of 6.1% in the risk of death at 28 days [10]. In light
of this evidence it was perhaps inevitable that drotrecogin
alfa would be used more widely [11] in patients, including
those with severe acute pancreatitis. A recent report
describes the use of this drug in two patients with severe
acute pancreatitis [12]. There was one death but the authors
conclude that the cases indicate the efficacy of drotrecogin
alfa in severe acute pancreatitis.
These reports highlight an acute dilemma in contemporary
critical care practice: there is a clear dearth of specific
treatment for severe acute pancreatitis, yet although
drotrecogin alfa holds promise in sepsis, is it safe for use in
severe acute pancreatitis? In the absence of specific clinical
trial evidence, pragmatic answers can be found in the details
of the PROWESS trial. Patients were included only if they
had new-onset organ dysfunction (sepsis-induced dys-
function of at least one organ or system that lasted no longer
than 24 hours) [10]. Although pancreatitis was a listed
exclusion criterion for the PROWESS trial, 3.4% of patients
receiving the drug had pancreatitis listed as a prior or pre-
existing condition. It is highly relevant that the main cause of
sepsis in patients in the PROWESS trial was of lung origin.
Primary intra-abdominal sepsis was the second most frequent
cause. A ‘serious bleeding event’ occurred in 30 patients
(3.5%) receiving drotrecogin alfa as compared with 17
patients (2%) receiving placebo. This difference was not
statistically significant (P = 0.06). The PROWESS trial
authors state that serious bleeding occurred primarily in
patients with an identifiable predisposition to bleeding.
Synthesis of these findings into a practical management
algorithm must accept that evidence in this field is changing
rapidly. Recognising that patients with severe acute
pancreatitis are currently being treated with drotrecogin alfa,
however, a practical position for current management would
be that, despite the experimental evidence of protein C
activation in the early stage of experimental acute
pancreatitis, there is insufficient evidence to justify the use of
drotrecogin alfa in the early stages of this disease. In the later
stages, when the probability of infection is proportionately
greater, it is probable that intensive care clinicians will turn to
drotrecogin alfa. In the setting of recent-onset organ
dysfunction in established severe acute pancreatitis there is
ample evidence that infection of pancreatic necrosis is a
major source of deterioration, and the availability of new
drugs must not blind clinicians to the need to search for, find
and treat infected pancreatic necrosis [13]. This need is
made more imperative by the risk of bleeding in untreated
peri-pancreatic sepsis.
In conclusion, drotrecogin alfa appears to represent a
genuine advance in the treatment of human sepsis but, in the
face of critical illness in severe acute pancreatitis, a vogue for
the use of new medications must not replace the need to
detect and treat infected pancreatic necrosis.
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